60 Degrees Pharmaceuticals (SXTP) News Today $0.83 +0.00 (+0.31%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period 60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given "Sell (E+)" Rating at Weiss RatingsJanuary 21 at 1:19 AM | americanbankingnews.com60 Degrees Pharmaceuticals' (SXTP) Neutral Rating Reiterated at HC WainwrightJanuary 13, 2025 | americanbankingnews.com60 Degrees Pharmaceuticals enrolls first patient in tafenoquine studyJanuary 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisJanuary 8, 2025 | globenewswire.com60 Degrees signs patent license deal with Tufts Medical, says H.C. WainwrightDecember 25, 2024 | markets.businessinsider.com60 Degrees, Tufts Medical Center announces patent license agreementDecember 24, 2024 | finance.yahoo.comSixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionDecember 23, 2024 | globenewswire.com60 Degrees expands tafenoquine clinical trial to Brigham and Women’s HospitalDecember 12, 2024 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for 60 Degrees Pharmaceuticals, Inc. (SXTP)December 12, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalDecember 11, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's HospitalDecember 11, 2024 | globenewswire.comInsider Buying: 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) CEO Buys 17,549 Shares of StockDecember 10, 2024 | insidertrades.com60 degrees pharmaceuticals CEO Geoffrey Dow acquires $6,367 in stockNovember 23, 2024 | investing.com60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNovember 14, 2024 | globenewswire.com60 Degrees (NASDAQ:SXTP) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.com60 Degrees (NASDAQ:SXTP) Stock, Short Interest ReportOctober 4, 2024 | benzinga.com60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchOctober 3, 2024 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSeptember 7, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSeptember 4, 2024 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsAugust 28, 2024 | globenewswire.com60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses ExpectationsAugust 18, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Second Quarter 2024 ResultsAugust 14, 2024 | globenewswire.comShould You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?August 12, 2024 | msn.comWhy Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?August 12, 2024 | investorplace.comUpcoming Stock Splits This Week (August 12 to August 16) – Stay InvestedAugust 12, 2024 | msn.com60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb StudyAugust 12, 2024 | globenewswire.com60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade SupportAugust 6, 2024 | finanznachrichten.de60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock SplitAugust 6, 2024 | globenewswire.comSixty Degrees Pharmaceuticals: 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade SupportJuly 25, 2024 | finanznachrichten.de60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportJuly 25, 2024 | finance.yahoo.comDow Tumbles Over 100 Points; American Express Earnings Beat ViewsJuly 20, 2024 | msn.com(XS2531438351.SG)July 20, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyJuly 20, 2024 | markets.businessinsider.comWhy Are 60 Degrees Pharmaceuticals Shares Up By 50% Today?July 20, 2024 | msn.com60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyJuly 19, 2024 | globenewswire.comWhy Is 60 Degrees (SXTP) Stock Up 56% Today?July 19, 2024 | investorplace.com60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior TreatmentJuly 9, 2024 | globenewswire.comFirst Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its KindJune 27, 2024 | globenewswire.comEnrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindMay 30, 2024 | globenewswire.com60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyMay 20, 2024 | globenewswire.comBalancing Act: Hold Rating Amid Positive Earnings and Upcoming Babesiosis Trial UncertaintiesMay 16, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsMay 15, 2024 | globenewswire.com60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesMay 8, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesMay 8, 2024 | globenewswire.com60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredMay 2, 2024 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) Price Target Increased by 8.33% to 1.33April 18, 2024 | msn.com60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisApril 3, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisApril 3, 2024 | globenewswire.com60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024March 14, 2024 | globenewswire.com60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisFebruary 20, 2024 | finance.yahoo.com Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address SXTP Media Mentions By Week SXTP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SXTP News Sentiment▼0.330.48▲Average Medical News Sentiment SXTP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SXTP Articles This Week▼21▲SXTP Articles Average Week Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EGRX News Today AIMD News Today ADXN News Today NLSP News Today SNGX News Today ORGS News Today VRAX News Today RDHL News Today VIRX News Today APM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SXTP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTP Stock Alerts